Portal de Periódicos da CAPES

Different epidemiology of bloodstream infections in COVID-19 compared to non-COVID-19 critically ill patients: a descriptive analysis of the Eurobact II study

2022; BioMed Central; Volume: 26; Issue: 1 Linguagem: Inglês

10.1186/s13054-022-04166-y

1466-609X

Niccolò Buetti, Alexis Tabah, Ambre Loiodice, Stéphane Ruckly, Abdullah Tarık Aslan, Giorgia Montrucchio, Andrea Cortegiani, Neşe Saltoğlu, Bircan Kayaaslan, Firdevs Aksoy, Akova Murat, Özlem Akdoğan, Kemal Tolga Saraçoğlu, Cem Erdoğan, Marc Léone, Ricard Ferrer, José Artur Paiva, Yoshiro Hayashi, Mahesh Ramanan, Andrew Conway Morris, François Barbier, Jean‐François Timsit, Jeffrey Lipman, Edward Litton, Anna Maria Palermo, Timothy A. Yap, Ege Eroglu, Koji Hosokawa, Hideki Yoshida, Shigeki Fujitani, Farid Zand, Ata Mahmoodpoor, Seyed Mohammad Nasiraldin Tabatabaei, Omar Elrabi, Ghaleb A. Almekhlafi, Gabriela Pereira Vidal, Marta Aparicio, Irene Alonzo, Silvio A. Ñamendys‐Silva, Mariana Hermosillo, Roberto Alejandro Castillo, Liesbet De Bus, Jan J. De Waele, Isabelle Hollevoet, Nicolas De Schryver, Nicolas Serck, Peđja Kovačević, Biljana Zlojutro, Étienne Ruppé, Philippe Montravers, Thierry Dulac, Jérémy Castanera, Alexandre Massri, Charlotte Guesdon, Pierre Garçon, Matthieu Duprey, François Philippart, Marc Tran, Cédric Bruel, Pierre Kalfon, Gaëtan Badre, Sophie Demeret, Loïc Le Guennec, Matteo Bassetti, Daniele Roberto Giacobbe, Gabriele Sales, Ivan Daroui, Giovanni Lodi, Mariachiara Ippolito, Davide Bellina, Andrea Di Guardo, Monica Rocco, Silvia Fiorelli, Adam Mikstacki, Mariusz Peichota, Iwona Pietraszek-Grzywaczewska, Pedro Póvoa, Andriy Krystopchuk, Ana Teresa, António Manuel Pereira de Figueiredo, Isabel Botelho, Vasco Costa, Rui Pedro Cunha, А. И. Грицан, Vladislav Belskiy, Mikhail Furman, Maria Martinez, Vanessa Casares, María Pilar Gracia Arnillas, Rosana Munoz Bermudez, Alejandro Úbeda, María Salgado, Emilio Maseda, Alejandro Suárez-de-la-Rica, Miguel Ángel Blasco-Navalpotro, Alberto Orejas Gallego, J Prazák, Jl Pagani, S. Abed-Maillard, Arzu Topeli̇, Selcuk Mehtap, Solakoğlu Ceyhun, Ayşe Kaya Kalem, Ibrahim Kurt, Murat Tellı, Barcin Ozturk, Nurcan Baykam, Rıdvan Karaali, Iftihar Koksal, Yelíz Bílír, Seda Guzeldağ, Gülden Ersöz, Guliz Evik, Yaşar Bayındır, Yasemin Ersoy, Ari Ercole, Ashok Raj, Artemis Zormpa, George Tinaslanidis, Reena Khade, Ashraf Roshdy, Santhana Kannan, Supriya Antrolikar, Nicholas Marsden, Ben Attwood, Jamie Patel, Mohan Gurjar, Carol D'Silva, Jagadish Chandran, Bashir El Sanousi, Elfayadh Saidahmed, Hytham K. S. Hamid,

Nosocomial Infections in ICU

Abstract Background The study aimed to describe the epidemiology and outcomes of hospital-acquired bloodstream infections (HABSIs) between COVID-19 and non-COVID-19 critically ill patients. Methods We used data from the Eurobact II study, a prospective observational multicontinental cohort study on HABSI treated in ICU. For the current analysis, we selected centers that included both COVID-19 and non-COVID-19 critically ill patients. We performed descriptive statistics between COVID-19 and non-COVID-19 in terms of patients’ characteristics, source of infection and microorganism distribution. We studied the association between COVID-19 status and mortality using multivariable fragility Cox models. Results A total of 53 centers from 19 countries over the 5 continents were eligible. Overall, 829 patients (median age 65 years [IQR 55; 74]; male, n = 538 [64.9%]) were treated for a HABSI. Included patients comprised 252 (30.4%) COVID-19 and 577 (69.6%) non-COVID-19 patients. The time interval between hospital admission and HABSI was similar between both groups. Respiratory sources (40.1 vs. 26.0%, p < 0.0001) and primary HABSI (25.4% vs. 17.2%, p = 0.006) were more frequent in COVID-19 patients. COVID-19 patients had more often enterococcal (20.5% vs. 9%) and Acinetobacter spp. (18.8% vs. 13.6%) HABSIs. Bacteremic COVID-19 patients had an increased mortality hazard ratio (HR) versus non-COVID-19 patients (HR 1.91, 95% CI 1.49–2.45). Conclusions We showed that the epidemiology of HABSI differed between COVID-19 and non-COVID-19 patients. Enterococcal HABSI predominated in COVID-19 patients. COVID-19 patients with HABSI had elevated risk of mortality. Trial registration ClinicalTrials.org number NCT03937245 . Registered 3 May 2019.